ORAL CAVITY CANCER METASTATIC

This adverse event was reported 15 times

These drugs are most commonly taken by patients reporting ORAL CAVITY CANCER METASTATIC:

# Drug Count
0 CISPLATIN 3
1 FLUOROURACIL 3
2 FLUOROURACIL CREAM, 0.5% 3
3 ALENDRONATE SODIUM 2
4 GEMCITABINE 2
5 GEMCITABINE HYDROCHLORIDE 2
6 ADALIMUMAB 1
7 ALENDRONATE SODIUM TABLET 1
8 AMBRISENTAN 1
9 ANTACID 1
See all common drugs associated with ORAL CAVITY CANCER METASTATIC

ORAL CAVITY CANCER METASTATIC is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 BEDAQUILINE FUMARATE 1 0.0007
1 CLOFAZIMINE 1 0.0002
2 PYRAZINAMIDE 1 0.0001
3 TIZANIDINE HYDROCHLORIDE 1 0.0001
4 ALENDRONATE SODIUM TABLET 1 0.0001
5 INSULIN DEGLUDEC 1 0.0000
6 FLUOROURACIL CREAM, 0.5% 3 0.0000
7 FLUOROURACIL 3 0.0000
8 CISPLATIN 3 0.0000
9 GEMCITABINE HYDROCHLORIDE 2 0.0000
See all drugs enriched for association with ORAL CAVITY CANCER METASTATIC

ORAL CAVITY CANCER METASTATIC is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Antimycobacterial [EPC] 1 0.0000
1 Oxazolidinone Antibacterial [EPC] 1 0.0000
2 Integrin Receptor Antagonist [EPC] 2 0.0000
3 Platinum-based Drug [EPC] 3 0.0000
4 Nucleoside Metabolic Inhibitor [EPC] 3 0.0000
5 Microtubule Inhibitor [EPC] 1 0.0000
6 Endothelin Receptor Antagonist [EPC] 1 0.0000
7 Vitamin D [EPC] 1 0.0000
8 Vitamin B12 [EPC] 1 0.0000
9 Vitamin C [EPC] 1 0.0000
See all drug classes enriched for association with ORAL CAVITY CANCER METASTATIC